(Q48475898)

11 February 2018

title

Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure (English)

1 reference

11 February 2018

0 references

0 references

1 reference

congestive heart failure

1 reference

Lilleberg J

1

1 reference

11 February 2018

Laine M

2

1 reference

11 February 2018

Palkama T

3

1 reference

11 February 2018

Kivikko M

4

1 reference

11 February 2018

Pohjanjousi P

5

1 reference

11 February 2018

Kupari M

6

1 reference

11 February 2018

publication date

7 July 2006

1 reference

11 February 2018

European Journal of Heart Failure

published in

1 reference

11 February 2018

volume

9

1 reference

11 February 2018

issue

1

1 reference

11 February 2018

page(s)

75-82

1 reference

11 February 2018

Haemodynamic dose-efficacy of levosimendan in healthy volunteers.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

Sustained hemodynamic effects of intravenous levosimendan

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

The natriuretic-peptide family

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2006.04.012

10.1016/J.EJHEART.2006.04.012

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018